Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Cingulate Inc (CING)
NASDAQ:CING
Holding CING?
Track your performance easily
CING Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.80 - $152.40
Previous Close$4.7
Volume181.32K
Average Volume (3M)321.30K
Market Cap
$14.47M
Enterprise Value$5.33M
Total Cash (Recent Filing)$10.00M
Total Debt (Recent Filing)$234.17K
Price to Earnings (P/E)―
Beta4.97
Next Earnings
Mar 07, 2025EPS Estimate
-$1.25Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-85.79
Shares Outstanding3,212,233
10 Day Avg. Volume346,769
30 Day Avg. Volume321,304
Standard Deviation0.35
R-Squared0.02
Alpha-0.07
Financial Highlights & Ratios
Price to Book (P/B)1.20
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-0.51
Forecast
1Y Price Target
$41.50Price Target Upside892.82% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Cingulate Inc News
PremiumCompany Announcements
Cingulate Inc: Executive Pay Restored, Funding Up, FDA Study Launched
Bulls Say, Bears Say
Bulls Say
Financial PerformanceThe current valuation is very attractive, representing significant upside from the current share price and appropriately balancing out high risks with large upside opportunities.
RegulatoryThe ongoing stimulant shortages may also be a regulatory tailwind for Cingulate in regards to FDA flexibility and potential approval.
TechnologyCingulate's Precision Timed Release (PTR) drug delivery technology can deliver once-daily oral therapies that provide all day efficacy while eliminating the need for boosters.
Bears Say
Capital NeedsCingulate still needs capital to complete the Phase 1 Fed/Fast study and financing options are likely challenging and significantly dilutive.
Financial PerformanceOperating expenses were significantly higher than expected due to R&D expenses.
ManagementManagement did not provide forward guidance.
---
Ownership Overview
63.15% Insiders
0.09% Mutual Funds
<0.01% Other Institutional Investors
36.73% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
CING FAQ
What was Cingulate Inc’s price range in the past 12 months?
Cingulate Inc lowest stock price was $1.80 and its highest was $152.40 in the past 12 months.
What is Cingulate Inc’s market cap?
Currently, no data Available
When is Cingulate Inc’s upcoming earnings report date?
Cingulate Inc’s upcoming earnings report date is Mar 07, 2025 which is in 100 days.
How were Cingulate Inc’s earnings last quarter?
Cingulate Inc released its earnings results on Nov 07, 2024. The company reported -$1.83 earnings per share for the quarter, beating the consensus estimate of -$2.363 by $0.533.
Is Cingulate Inc overvalued?
According to Wall Street analysts Cingulate Inc’s price is currently Undervalued.
Does Cingulate Inc pay dividends?
Cingulate Inc does not currently pay dividends.
What is Cingulate Inc’s EPS estimate?
Cingulate Inc’s EPS estimate is -$1.25.
How many shares outstanding does Cingulate Inc have?
Cingulate Inc has 3,212,233 shares outstanding.
What happened to Cingulate Inc’s price movement after its last earnings report?
Cingulate Inc reported an EPS of -$1.83 in its last earnings report, beating expectations of -$2.363. Following the earnings report the stock price went up 2.381%.
Which hedge fund is a major shareholder of Cingulate Inc?
Among the largest hedge funds holding Cingulate Inc’s share is GoalVest Advisory LLC. It holds Cingulate Inc’s shares valued at N/A.
---
Cingulate Inc Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$41.50 (892.82% Upside)
$41.50 (892.82% Upside)
Hedge Fund Trend
Decreased
By 97.0 Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.2%
Last 30 Days ▼ 4.4%
Last 30 Days ▼ 4.4%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-94.91%
12-Months-Change
Fundamentals
Return on Equity
-273.82%
Trailing 12-Months
Asset Growth
131.34%
Trailing 12-Months
Company Description
Cingulate Inc
Cingulate Inc is a clinical stage biopharmaceutical company utilizing its proprietary precision timed release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes.
---
CING Stock 12 Month Forecast
Average Price Target
$41.50
▲(892.82% Upside)
Technical Analysis
Relmada Therapeutics
―
Axsome Therapeutics
―
Medicinova
―
SELLAS Life Sciences Group
―
Best Analysts Covering CING
1 Year
1 Year Success Rate
0/8 ratings generated profit
1 Year Average Return
-70.16%
upgraded a buy rating 8 days ago
Copying Naz Rahman's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -70.16% per trade.
---